Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
about
Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor modelLong-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.Proinflammatory Cytokines and Potassium Channels in the KidneyTumour Angiogenesis and Angiogenic Inhibitors: A ReviewToxicities of Immunotherapy for the PractitionerRecombinant IFN-α2a-NGR exhibits higher inhibitory function on tumor neovessels formation compared with IFN-α2a in vivo and in vitroInterferon Alpha Treatment and Thyroid DysfunctionIdentification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysisEbola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Inhibition of tumor cell motility by the interferon-inducible GTPase MxAVon Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura.Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.Safety considerations when treating myelofibrosis.Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.Interferon induced thyroiditis.Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.Hepatitis C and interferon induced thyroiditis.Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.Interaction between granulin A and enolase 1 attenuates the migration and invasion of human hepatoma cells.Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression.Targeted therapies in the management of renal cell carcinoma: role of bevacizumabDirect transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma.PhiC31/PiggyBac modified stromal stem cells: effect of interferon γ and/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on murine melanoma.Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma.Role of benzyl alcohol in the unfolding and aggregation of interferon α-2a.Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo.Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials.Mechanism and its regulation of tumor-induced angiogenesis.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Cytokine and anticytokine therapy in dermatology.A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.Thyroid dysfunction from antineoplastic agents.The role of biological response modifiers in malignant melanoma.BID is a critical factor controlling cell viability regulated by IFN-α.Clinical and epidemiologic burden of chronic myelogenous leukemia.IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma
P2860
Q24612339-A341139C-0DA9-4A90-893F-CF9510CEC618Q24813821-07BE0A7A-9B9F-41AF-9BA5-06690413F37BQ26778327-527818C5-3E96-4E6B-957B-54A345A4DAC1Q26798822-5E847555-89BA-43E4-A956-F89290B46084Q27008140-2B2B70FF-7FF9-42D2-B886-14348A658241Q27316848-B4B6616B-FCB6-422B-9ABD-5A0F5AB00B9CQ27483686-443109C6-A756-4592-BE25-C2E632828755Q28481496-F1B5BD34-9C2D-4A4D-8B50-9B1C36B87A50Q30251949-5E1037A0-6A6C-4588-BB0F-FDACF3A4E1A4Q30487769-8CB749AA-3653-4792-A5C9-05C23434A51DQ33366113-BE3A997B-2E66-4E4E-A37B-DC033F4E6830Q33394175-1F3FE065-1538-400E-A8FF-0312347F3A13Q33415592-F81AE83B-6C95-4E47-AAB1-0C52DD0EE036Q33432285-E8F7FD3C-3E9F-4E59-8D25-3045876D0DC7Q33509884-DBBF8A98-681E-42BB-8324-3886BBA2B68DQ33636049-8811CA20-DABA-4FDF-B981-92B98CE9C922Q33713956-B3EA07F6-25DF-49BD-A583-AC42A8D3318BQ33716540-66BE8004-2ED4-47A8-886D-B3FB6323FDF7Q33721389-F33704BA-2FF1-47AA-8F6C-388A96328D3DQ33728307-939593D1-4AE5-426F-9504-16C04DD31F11Q33788697-547A7422-D7C2-4015-B531-8E5BE7221EE3Q33923147-BB33771F-395A-4D51-9505-DF85CB763D8DQ34473352-0FD2C490-8CFA-4B8A-9603-2C5B7B3B35F6Q34558610-18F3B15C-9557-4409-850A-79F312D15408Q34611205-DD0D7F4E-D8CB-4FB1-8BB4-45074E761F2FQ34634386-FAD8D1EF-C9B6-4586-8AA6-E057D166939CQ34649457-EB016CEC-3915-4085-98DD-54AEEC4CC954Q34990410-5750476A-38E7-4D32-98CA-7F7953B23672Q35032786-A7B167E1-E52D-41BD-9BC4-4681BB4F82D9Q35070806-F2DC068D-F31A-4787-A53C-40935F6AD5A9Q35101345-395E688A-D994-432D-AC69-561A3B07B58FQ35151099-FBE1200E-BD95-428E-A77F-2AB1160E4DD5Q35163167-5A69C4BA-FE50-46D9-A5FB-BEAFDDBC35AEQ35184711-CF63E82E-DFFC-493B-9E4E-CC62407130CBQ35212620-178ADF2A-87C8-4A02-A815-8CF845C4DF3AQ35500038-A7E86078-DFF1-4BEA-9D3A-F0479CD763C8Q35594064-4A899B71-6E80-462E-8C4E-A1F85363A263Q35621716-DB2C3FBB-45F5-4607-A631-0E971E39E78EQ35641216-212C7399-35C9-4357-934E-A418F9B66BF0Q35750929-C9AB50DA-C5C5-474C-9C76-9DD37820EADD
P2860
Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interferon in oncological prac ...... applications, and toxicities.
@ast
Interferon in oncological prac ...... applications, and toxicities.
@en
Interferon in oncological prac ...... applications, and toxicities.
@nl
type
label
Interferon in oncological prac ...... applications, and toxicities.
@ast
Interferon in oncological prac ...... applications, and toxicities.
@en
Interferon in oncological prac ...... applications, and toxicities.
@nl
prefLabel
Interferon in oncological prac ...... applications, and toxicities.
@ast
Interferon in oncological prac ...... applications, and toxicities.
@en
Interferon in oncological prac ...... applications, and toxicities.
@nl
P1433
P1476
Interferon in oncological prac ...... applications, and toxicities.
@en
P2093
F G Haluska
P356
10.1634/THEONCOLOGIST.6-1-34
P577
2001-01-01T00:00:00Z